Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus bevacizumab + anecortave acetate for exudative age-related macular degeneration
2006-003170-99Phase 2Active
- Sponsor
- University of Udine
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab and anecortave in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by University of Udine. Primary endpoints: Number of bevacizumab retreatments at 12 months and Mean change in best corrected visual acuity. Started Mar 2007; status: active.
02
Drugs
bevacizumabanecortave
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-003170-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003170-99.